Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91%
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

EV/FCFF
Enterprise Value to FCFF

-9.3
Current
-8.9
Median
3.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-9.3
=
Enterprise Value
2.3B SEK
/
FCFF
-246.6m SEK
All Countries
Close
 
SE
Egetis Therapeutics AB (publ)
STO:EGTX
Average EV/FCFF: 29.8
Negative Multiple: -9.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -239 140.5
US
Abbvie Inc
NYSE:ABBV
23.6
US
Amgen Inc
NASDAQ:AMGN
30.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -72.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -469
AU
CSL Ltd
ASX:CSL
62.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -106.2

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More